Business context and reporting period
The supplied filing is Sigma Labs, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified as Nexttrip, Inc. Sigma Labs develops manufacturing and materials technologies, focusing on real-time quality assurance for additive manufacturing, consulting services, and metal 3D-printing contract manufacturing.
Key financial metrics
| Metric | Q1 2015 / March 31, 2015 | Comparable period / prior year-end |
|---|---|---|
| Revenue | $185,686 | $114,829 in Q1 2014 |
| Gross profit and margin | $160,819; 86.6% | $58,940; 51.3% in Q1 2014 |
| Operating expenses | $533,260 | $526,688 in Q1 2014 |
| Net loss | $371,881 | $466,906 in the financial statements for Q1 2014; MD&A gives $467,095 |
| Operating cash flow | $(463,705) | $(300,504) in Q1 2014 |
| Cash | $2,489,660 | $2,962,069 at December 31, 2014 |
| Working capital | $2,594,753 | $2,811,606 at December 31, 2014 |
| Total liabilities | $143,451; no debt reported | $354,350 at December 31, 2014 |
Revenue rose about 62% year over year, while the net loss narrowed. Cash declined by $472,409 during the quarter, primarily reflecting operating cash use and $8,704 of investing outflows; there were no financing proceeds. Basic and diluted loss per share were each reported as $(0.00), reflecting rounding.
Material changes versus the prior comparable period
- Revenue increased by $70,857, which management attributed primarily to additional ongoing contracts. Revenue was mainly from engineering consulting; technology sales remained limited.
- Cost of service revenue fell to $24,867 from $55,889, contributing to the higher gross margin.
- Research and development expense rose from zero to $70,147, associated with increased PrintRite3D development activity. Stock compensation expense also increased materially.
- Payroll expense decreased, mainly because Q1 2014 included a $175,000 CEO performance bonus.
- Operating cash use increased year over year. Cash and working capital remained substantial relative to reported current liabilities but declined from year-end.
Outlook, commentary, risks, and unusual items
- Management expected available funds, consulting receipts, and anticipated securities-sale proceeds to support operations through 2016; this is an estimate, not a guarantee. The company had no credit facility or committed third-party capital.
- As of May 14, 2015, four active consulting contracts were expected to generate up to approximately $680,000 during the remainder of 2015, subject to performance milestones. Part of the GE Aviation-led project was delayed, with some revenue expected to shift to Q1 2016.
- Management expected higher 2015 spending on commercialization, marketing, sales, employees, and consultants. It anticipated further PrintRite3D commercialization efforts in 2015–2016 and contract-manufacturing revenue from its EOS M290 printer.
- Fixed-price contracts expose the company to cost-estimation and execution risk: overruns could reduce or eliminate expected profits. Continued operations and commercialization depend on contract revenue, partnerships, manufacturing orders, and/or additional financing; new securities could dilute existing shareholders, and funding is not assured.
- After quarter-end, the company announced a Honeywell PrintRite3D system sale and opened its metal-printing facility. These developments do not constitute Q1 revenue. The filing states no subsequent events requiring financial-statement disclosure.
- The company reported no legal proceedings, no off-balance-sheet arrangements, and no material change in internal control over financial reporting. Its effective S-3 registration statement permitted offerings up to $100 million, with a separate at-the-market agreement up to $25 million; no securities had been sold under it by March 31, 2015, and the company said it was then ineligible to use the S-3 because its nonaffiliate public float was below the required threshold.
Important facts an investor should verify
- Confirm the intended issuer: this filing is for Sigma Labs, Inc., whereas the request metadata names Nexttrip, Inc.
- Reconcile the filing’s Q1 2014 net-loss figures: $466,906 in the statements versus $467,095 in MD&A and the loss-per-share note.
- Reconcile expense disclosures: the statements report payroll expense of $72,660 and stock compensation of $122,750, while MD&A reports $71,366 and $124,044, respectively.
- Assess whether the conditional contract pipeline, GE project timing, and management’s stated funding horizon support the anticipated cash needs and commercialization plans.
- Review potential dilution, including substantial common shares outstanding, unvested stock awards, outstanding warrants, and any future securities offerings.